Minimal Residual Disease MRD Analysis for B-ALL Test
Understanding Minimal Residual Disease in B-Cell Acute Lymphoblastic Leukemia
Minimal Residual Disease (MRD) refers to the small number of cancer cells that remain in the body after treatment, even when standard testing methods show no evidence of disease. The MRD Analysis for B-ALL Test represents a breakthrough in leukemia monitoring, providing unprecedented sensitivity in detecting these residual cancer cells that could lead to relapse if left undetected.
What This Advanced Test Measures
Our comprehensive MRD analysis utilizes state-of-the-art flow cytometry technology to detect and quantify residual leukemia cells with exceptional precision. The test specifically targets B-cell Acute Lymphoblastic Leukemia by analyzing multiple critical cell surface markers:
- CD10, CD19, CD20 – B-cell lineage markers
- CD34, CD38 – Stem cell and activation markers
- CD45 – Leukocyte common antigen
- CD13, CD15, CD33, CD123 – Myeloid and activation markers
- CD58, CD73, CD86, CD200 – Co-stimulatory and regulatory markers
- SYTO-16 – Nuclear staining for cell viability
Who Should Consider MRD Testing
Clinical Indications and Patient Profiles
This specialized test is recommended for patients who have been diagnosed with B-cell Acute Lymphoblastic Leukemia and are undergoing or have completed treatment. Specific indications include:
- Patients currently receiving chemotherapy or targeted therapy for B-ALL
- Individuals who have achieved morphological complete remission
- Patients being considered for treatment intensification or reduction
- Those preparing for stem cell transplantation
- Patients with previous B-ALL diagnosis being monitored for potential relapse
- Individuals with unexplained blood count abnormalities post-treatment
Significant Benefits of MRD Monitoring
Transforming Leukemia Management
Regular MRD assessment provides numerous clinical advantages that significantly impact patient outcomes and treatment strategies:
- Early Relapse Detection: Identify disease recurrence months before clinical symptoms appear
- Treatment Guidance: Inform decisions about therapy intensification or de-escalation
- Prognostic Information: Provide valuable insights into long-term survival probabilities
- Transplant Timing: Optimize timing for stem cell transplantation procedures
- Reduced Overtreatment: Prevent unnecessary aggressive therapy in MRD-negative patients
- Peace of Mind: Offer reassurance through objective disease monitoring
Understanding Your Test Results
Interpreting MRD Analysis Findings
Your MRD test results will provide critical information about your disease status and treatment response:
- MRD-Negative: No detectable leukemia cells found, indicating excellent treatment response
- Low-Level MRD: Minimal residual disease detected, suggesting continued monitoring needed
- Persistent MRD: Significant residual disease requiring treatment adjustment
- Increasing MRD: Rising levels indicating potential relapse risk
Your oncologist will interpret these results in the context of your specific clinical situation, treatment history, and overall health status to develop the most appropriate management plan.
Test Pricing and Availability
| Test Name | Discount Price | Regular Price |
|---|---|---|
| Minimal Residual Disease MRD Analysis for B-ALL Test | $350 USD | $476 USD |
Sample Requirements and Processing
Sample Type: 3 mL (1 mL minimum) First pull Bone Marrow aspirate in 1 Green Top (Sodium Heparin) tube
Shipping Instructions: Ship immediately at 18-22°C. DO NOT FREEZE
Turnaround Time: Sample Daily by 9 am; Report Next Working Day
Mandatory Information Required: Date & Time of sampling, Previous immunophenotype report & Clinical history
Nationwide Testing Availability
We proudly serve patients across the United States with convenient testing locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our network of certified collection centers ensures accessible testing for patients nationwide.
Take Control of Your Leukemia Management
Don’t leave your remission status to chance. The MRD Analysis for B-ALL Test provides the precise monitoring needed to guide your treatment journey effectively. Early detection of residual disease can make a significant difference in long-term outcomes and quality of life.
Ready to schedule your test? Contact our specialized oncology testing team today at +1(267) 388-9828 or book your appointment online. Our experienced staff will guide you through the process and ensure your sample is handled with the utmost care and precision.
Take the next step in comprehensive leukemia monitoring and gain the valuable insights needed to optimize your treatment strategy and achieve the best possible outcomes.
